Research Topics
Species | M ToftSummaryAffiliation: Norwegian University of Science and Technology Country: Norway Publications
| Collaborators
|
Detail Information
Publications
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian populationM Toft
Department of Neuroscience, Norwegian University of Science and Technology, N 7489 Trondheim, Norway
Neurology 66:415-7. 2006..Seven patients (2.3%) and 8 controls (1.7%) carried a mutant GBA allele (p = 0.58). This study does not indicate increased susceptibility to PD in GBA mutations carriers in Norway...
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's diseaseLinda R White
Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
J Neurosci Res 85:1288-94. 2007..Such changes may also be shown in blood samples during the preclinical stage of LRRK2-associated PD, which could be particularly important for the development of neuroprotective strategies to delay onset, or slow progression of PD...
LRRK2 mutations are not common in Alzheimer's diseaseMathias Toft
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL, USA
Mech Ageing Dev 126:1201-5. 2005..However, these results do not exclude a possible role of other genetic variants within the LRRK2 gene in AD or other forms of dementia...
PINK1 mutation heterozygosity and the risk of Parkinson's diseaseM Toft
Department of Neuroscience, Norwegian University of Science and Technology NTNU, N 7489 Trondheim, Norway
J Neurol Neurosurg Psychiatry 78:82-4. 2007..Mutations in the PTEN-induced kinase 1 (PINK1) gene have been identified in recessively inherited and sporadic early-onset parkinsonism (EOP)...
Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian populationR Myhre
Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, Trondheim, Norway
Acta Neurol Scand 118:320-7. 2008..Our aim was to study SNCA gene markers in a closely matched Norwegian PD population to examine the genetic relationship between different polymorphisms associated with the disease...
LRRK2 and Parkinson's disease in NorwayM Toft
Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
Acta Neurol Scand Suppl 187:72-5. 2007..Herein, we investigate the frequency of a number of recently identified LRRK2 mutations in Norway...
Lrrk2 R1441 substitution and progressive supranuclear palsyO A Ross
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
Neuropathol Appl Neurobiol 32:23-5. 2006..No evidence was found for the presence of a mutation at this codon in our series. These data would suggest that this Lrrk2 variant does not contribute in susceptibility to PSP...
Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusionsJustus C Dachsel
Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Acta Neuropathol 113:601-6. 2007..These findings may be coincidental; however, there is a small nucleus of LRRK2-positive patients displaying atypical features suggesting a role for this protein in other neurodegenerative disorders...
Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's diseaseMathias Toft
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
Mov Disord 22:389-92. 2007..3; 95% CI: 0.6-2.8; P = 0.45). These findings highlight the importance of using family-based studies and multiple population screenings when examining the association of these polymorphic LRRK2 gene variants with Parkinson's disease...
ELAVL4, PARK10, and the CeltsKristoffer Haugarvoll
Department of Neuroscience and Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA
Mov Disord 22:585-7. 2007..Our data suggest that the association between ELAVL4 and PD previously observed might be explained by a Celtic-founder effect...
Clinical heterogeneity of the LRRK2 G2019S mutationSpiridon Papapetropoulos
Department of Neurology, University of Miami School of Medicine, Miami, FL, USA
Arch Neurol 63:1242-6. 2006..The "common" LRRK2 G2019S kinase domain substitution has been reported to account for approximately 5% of familial and 1% of sporadic Parkinson disease...
Lrrk2 and Lewy body diseaseOwen A Ross
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
Ann Neurol 59:388-93. 2006..The Lrrk2 kinase domain G2019S substitution is the most common genetic basis of familial and sporadic parkinsonism. Patients harboring the G2019S substitution usually present with clinical Parkinson's disease...
Genomewide association, Parkinson disease, and PARK10Matthew J Farrer
Am J Hum Genet 78:1084-8; author reply 1092-4. 2006
Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PDDavid Gosal
Department of Neurology, Mater Misericordiae Hospital, Eccles St, Dublin 7, Ireland
Parkinsonism Relat Disord 11:349-52. 2005..The influence of the G2019S substitution on protein function and disease phenotype has yet to be fully resolved, but its elucidation will undoubtedly further our understanding of the mechanisms underlying Parkinson's disease...
Clinical features of LRRK2-associated Parkinson's disease in central NorwayJan O Aasly
Department of Neurology, St Olav s Hospital, Trondheim, Norway
Ann Neurol 57:762-5. 2005..The clinical features included asymmetric resting tremor, bradykinesia, and rigidity with a good response to levodopa and could not be distinguished from idiopathic Parkinson's disease...
LRRK2 mutations and ParkinsonismMathias Toft
Lancet 365:1229-30. 2005
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populationsJennifer Kachergus
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Am J Hum Genet 76:672-80. 2005..Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis...
Corticobasal syndrome and primary progressive aphasia as manifestations of lrrk2 gene mutationsOwen A Ross
Neurology 71:303; author reply 303-4. 2008
Variants in the LRRK1 gene and susceptibility to Parkinson's disease in NorwayKristoffer Haugarvoll
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida, USA, and Department of Neurology, St Olav s Hospital, Trondheim, Norway
Neurosci Lett 416:299-301. 2007..Two rare coding variants ss65713826 and ss65713830 were more frequent in patients than controls. However, their identification in healthy controls and lack of co-segregation with disease suggests they may represent benign polymorphisms...
[The genetics of Parkinson disease]Mathias Toft
Institutt for nevromedisin, Det medisinske fakultet, Norges teknisk-naturvitenskapelige universitet
Tidsskr Nor Laegeforen 124:922-4. 2004..INTERPRETATION: The genes and loci identified have improved our understanding of the pathogenesis in PD significantly. This knowledge may help to create new treatment strategies for PD...
[Malignant hyperthermia--a hereditary and potentially life-threatening condition]Tonje Haugen
Department of Public Health, University of North Florida, USA
Tidsskr Nor Laegeforen 125:2792-4. 2005..A contracture test of muscular tissue is performed in patients with suspected malignant hyperthermia and should be considered in family members. Molecular genetic examinations might be considered in some cases...
FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophyValerie Biancalana
Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasburg, France
Arch Neurol 62:962-6. 2005..It has been proposed that FXTAS might be a common neurodegenerative disorder...
Linkage disequilibrium and association of MAPT H1 in Parkinson diseaseLisa Skipper
Laboratories of Neurogenetics, Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Am J Hum Genet 75:669-77. 2004..Using a sliding scale of MAPT H1-specific haplotypes--in age/sex-matched PD cases and controls from central Norway--we have refined the disease association to within an approximately 90-kb interval of the 5' end of the MAPT locus...
[Treatment of movement disorders with deep brain stimulation]Mathias Toft
Nevrologisk avdeling, Nevroklinikken, Rikshospitalet, 0027 Oslo
Tidsskr Nor Laegeforen 128:1972-6. 2008..We also present data om the activity related to patients with Parkinson's disease in a representative year and data on implantations performed Rikshospitalet University Hospital in the period 1999-2007...
